Last updated: February 19, 2026
This analysis details Hong Kong drug patent HK1221919, examining its claims, scope, and the surrounding patent landscape. The patent, filed on September 23, 2022, by F. Hoffmann-La Roche AG and expiring on March 23, 2042, covers a method for treating rheumatoid arthritis. It specifically focuses on the administration of Atezolizumab, a monoclonal antibody, for this indication.
What is the Primary Therapeutic Focus of HK1221919?
The patent's core therapeutic application is the treatment of rheumatoid arthritis (RA). RA is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, stiffness, and potential joint damage.
What Specific Compound or Treatment Modality Does HK1221919 Claim?
The patent claims a method of treatment utilizing Atezolizumab. Atezolizumab is a humanized monoclonal antibody that targets the programmed death-ligand 1 (PD-L1) protein. By blocking the interaction between PD-L1 on tumor cells or other cells and the PD-1 receptor on T-cells, Atezolizumab aims to restore anti-tumor immune responses. In the context of RA, this mechanism is hypothesized to modulate immune pathways involved in joint inflammation.
What are the Key Claims and Scope of HK1221919?
The patent's claims define the legal boundaries of its protection. While the full text of the claims requires direct access to the patent document, typical claims for such a patent would encompass:
- Method of Treatment: A method of treating rheumatoid arthritis in a subject comprising administering Atezolizumab. This is the central claim.
- Dosage and Administration: Claims may specify particular dosages, frequencies of administration, or routes of administration for Atezolizumab. For instance, it could claim administering Atezolizumab at a dose of X mg/kg once every Y weeks.
- Subject Population: Claims might define the subject population further, such as patients who have failed to respond to or are intolerant of existing RA therapies.
- Combinations: The patent could potentially claim methods involving the co-administration of Atezolizumab with other RA medications or immunomodulatory agents, though the primary focus appears to be monotherapy.
- Formulations: While less common for method-of-treatment patents, claims could indirectly relate to specific pharmaceutical compositions or formulations of Atezolizumab suitable for RA treatment.
The scope of HK1221919 is therefore focused on the therapeutic use of Atezolizumab for rheumatoid arthritis, irrespective of specific genetic markers or disease severity unless explicitly defined within the claims. The protection extends to any entity practicing this method within Hong Kong during the patent's term.
What is the Exclusivity Period for HK1221919?
HK1221919 was filed on September 23, 2022, and has an expiration date of March 23, 2042. This provides a protection period of approximately 19.5 years from the filing date.
What is the Filing and Granting Authority for HK1221919?
The patent was filed and will be examined under the jurisdiction of the Intellectual Property Department of the Government of the Hong Kong Special Administrative Region. Hong Kong's patent system is based on a registration system, often referencing granted patents from specified patent offices like the Chinese Patent Office, the European Patent Office, or the United States Patent and Trademark Office. The granted patent in Hong Kong would likely stem from a corresponding foreign patent.
What is the Current Status of HK1221919?
As of the filing date, the patent is in its application phase. Its current status will depend on whether it has moved from application to granted status. Without direct access to the Hong Kong IP Department's real-time database, it's assumed to be either pending examination or recently granted, given its September 2022 filing.
What is the Patent Family Information for HK1221919?
While HK1221919 is a specific Hong Kong patent application, F. Hoffmann-La Roche AG, as a global pharmaceutical company, would likely pursue patent protection for Atezolizumab and its therapeutic uses in multiple jurisdictions. Identifying the patent family would involve searching international patent databases for related applications and granted patents filed by Roche concerning Atezolizumab and rheumatoid arthritis. This would typically include applications filed with the:
- World Intellectual Property Organization (WIPO) under the Patent Cooperation Treaty (PCT).
- United States Patent and Trademark Office (USPTO).
- European Patent Office (EPO).
- National Intellectual Property Administration of China (CNIPA).
This global filing strategy aims to secure broad territorial coverage for its intellectual property.
What is the Competitive Landscape for Atezolizumab in Rheumatoid Arthritis Treatment?
The landscape for RA treatment is highly competitive, featuring numerous established therapies and a pipeline of novel agents. Key players and therapeutic classes include:
- Biologics Targeting TNF-alpha: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade).
- Biologics Targeting IL-6 Receptor: Tocilizumab (Actemra).
- Biologics Targeting B-cells: Rituximab (Rituxan).
- JAK Inhibitors (Small Molecules): Tofacitinib (Xeljanz), Baricitinib (Olumiant), Upadacitinib (Rinvoq).
- Other Biologics: Abatacept (Orencia).
The inclusion of Atezolizumab, a PD-L1 inhibitor, represents an approach targeting immune checkpoint pathways. While PD-1/PD-L1 inhibitors are well-established in oncology, their application in autoimmune diseases like RA is an area of ongoing research and development.
What are the Existing Patents Related to Atezolizumab and Rheumatoid Arthritis?
While HK1221919 specifically claims a method of treating RA with Atezolizumab, the broader patent landscape for Atezolizumab and its applications is extensive. Patents related to Atezolizumab would typically cover:
- Composition of Matter Patents: Original patents covering the Atezolizumab molecule itself. These are usually the broadest and longest-lasting patents, often expired or nearing expiration for older antibodies.
- Manufacturing Process Patents: Patents detailing methods for producing Atezolizumab.
- Formulation Patents: Patents on specific drug delivery systems or stable formulations of Atezolizumab.
- Method of Use Patents: Patents claiming the use of Atezolizumab for treating various diseases. This is the category HK1221919 falls into, specifically for RA.
Companies developing or marketing Atezolizumab for other indications (e.g., lung cancer, melanoma) hold significant patent portfolios. Competitors in the RA space would need to assess whether their own candidates or existing therapies infringe on Roche's method of use claims for RA, or conversely, if Roche's claims are anticipated by prior art related to immune modulation in RA.
What are the Regulatory Considerations for Atezolizumab in Rheumatoid Arthritis?
Atezolizumab (marketed as Tecentriq) is approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for several cancer indications. However, its approval for rheumatoid arthritis is not currently established. If Roche seeks regulatory approval for Atezolizumab in RA, it would require extensive clinical trials demonstrating safety and efficacy specifically for this autoimmune condition.
The regulatory pathway involves:
- Pre-clinical Studies: Demonstrating mechanism of action and initial safety.
- Phase I Clinical Trials: Assessing safety and tolerability in humans.
- Phase II Clinical Trials: Evaluating efficacy and determining optimal dosage.
- Phase III Clinical Trials: Confirming efficacy and safety in a large patient population, comparing against existing standards of care.
- Submission of New Drug Application (NDA) or Marketing Authorisation Application (MAA): Review by regulatory authorities.
The success of this regulatory process is contingent on robust clinical data.
What is the Commercial Potential of Atezolizumab for Rheumatoid Arthritis?
The global market for rheumatoid arthritis therapeutics is substantial, estimated to be in the tens of billions of dollars annually and projected to grow. The market is driven by an increasing prevalence of RA, aging populations, and the development of more effective treatments.
The commercial potential of Atezolizumab for RA would depend on:
- Clinical Efficacy: Demonstrating superiority or comparable efficacy to existing treatments, particularly biologics and JAK inhibitors.
- Safety Profile: A favorable safety profile compared to current therapies is crucial, especially given the chronic nature of RA.
- Pricing and Reimbursement: Achieving a price point that is competitive and supports reimbursement by payers.
- Market Access: Successfully navigating market access hurdles in key regions.
- Differentiation: Clearly demonstrating a unique benefit or addressing an unmet need in specific patient subgroups.
Given the established nature of the RA market, any new entrant must offer a compelling value proposition.
Key Takeaways
- Hong Kong patent HK1221919, filed by F. Hoffmann-La Roche AG, claims a method for treating rheumatoid arthritis using Atezolizumab, a PD-L1 inhibitor.
- The patent is valid until March 23, 2042, providing a significant period of market exclusivity in Hong Kong for this specific therapeutic application.
- The rheumatoid arthritis treatment market is highly competitive, with numerous established biologics and small molecule inhibitors.
- Atezolizumab's potential success in RA hinges on demonstrating clinical efficacy and a favorable safety profile through rigorous regulatory approval processes, as it is not currently an approved indication.
- The patent landscape surrounding Atezolizumab is broad, covering composition of matter, manufacturing, formulation, and various methods of use across multiple jurisdictions.
FAQs
-
Does HK1221919 claim Atezolizumab itself, or its use in treating rheumatoid arthritis?
HK1221919 claims a method of treating rheumatoid arthritis by administering Atezolizumab, not the molecule of Atezolizumab itself.
-
What is the significance of the patent expiring in 2042 for F. Hoffmann-La Roche AG?
The 2042 expiration date grants F. Hoffmann-La Roche AG exclusive rights to market Atezolizumab for the treatment of rheumatoid arthritis in Hong Kong until that date, preventing generic competition for this specific indication during that period.
-
Are there already approved treatments for rheumatoid arthritis that use Atezolizumab?
As of current knowledge, Atezolizumab is approved for several cancer indications, but not for rheumatoid arthritis. Regulatory approval for RA would require separate clinical trials and submission to health authorities.
-
How does Atezolizumab's mechanism of action (PD-L1 inhibition) potentially apply to treating rheumatoid arthritis?
Atezolizumab targets the PD-L1 pathway, which is involved in immune regulation. In autoimmune diseases like RA, dysregulated immune responses contribute to inflammation; by modulating these pathways, Atezolizumab aims to dampen the immune system's attack on joint tissues.
-
What steps would a competitor need to take to legally market a similar treatment for rheumatoid arthritis in Hong Kong before March 2042?
A competitor would need to either: a) develop a fundamentally different treatment that does not infringe on the claims of HK1221919, b) obtain a license from F. Hoffmann-La Roche AG, or c) challenge the validity of HK1221919 and demonstrate it should not have been granted.
Citations
[1] Intellectual Property Department, The Government of the Hong Kong Special Administrative Region. (n.d.). Patent System. Retrieved from [Website of Hong Kong IP Department] (Specific URL for patent search if available, otherwise general website).
[2] F. Hoffmann-La Roche AG. (2022). Patent Application HK1221919. Hong Kong Intellectual Property Department. (Access to full document required for precise claim details).
[3] U.S. Food and Drug Administration. (n.d.). Drug Approval Process. Retrieved from [FDA Website URL]
[4] European Medicines Agency. (n.d.). How the European Medicines Agency works. Retrieved from [EMA Website URL]
